Browsed by
Tag: experimental

The New Way of BioViva – Interview with Liz Parrish by Ariel VA Feinerman

The New Way of BioViva – Interview with Liz Parrish by Ariel VA Feinerman

Ariel VA Feinerman
Elizabeth Parrish


Interview with Liz Parrish, CEO of BioViva

Liz Parrish, CEO of BioViva

Preface

What is ageing? We can define ageing as a process of accumulation of the damage which is just a side-effect of normal metabolism. While researchers still poorly understand how metabolic processes cause damage accumulation, and how accumulated damage causes pathology, the damage itself — the structural difference between old tissue and young tissue — is categorized and understood pretty well. By repairing damage and restoring the previously undamaged — young — state of an organism, we can really rejuvenate it! Sounds very promising, and so it is. And for some types of damage (for example, for senescent cells), it is already proved to work!

Today in our virtual studio somewhere between Saint-Petersburg and Seattle, we meet a famous person! Elizabeth Parrish, CEO of BioViva, is a humanitarian, entrepreneur, innovator, and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of regenerative medicine modalities, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach and is a founding member of the International Longevity Alliance (ILA). She is an affiliated member of the Complex Biological Systems Alliance (CBSA), which is a unique platform for Mensa-based, highly gifted persons who advance scientific discourse and discovery.

The mission of the CBSA is to further scientific understanding of biological complexity and the nature and origins of human disease. She is the founder of BioTrove Investments LLC and the BioTrove Podcasts, which is committed to offering a meaningful way for people to learn about and fund research in regenerative medicine.

Interview

Ariel Feinerman: Hello, Ms. Liz Parrish!

Liz Parrish: Hello, Ariel Feinerman!

Ariel Feinerman: Honestly, I have planned to offer you the idea of building the whole infrastructure for delivering therapies from manufacturers via clinics to the patients. Because we really need such an infrastructure! By the way, when I looked at BioViva web page, I could see that you already do that! Very nice surprise for all. Can you say, when and why you realised that making therapy is not enough and that to build a viable alternative to the usual regulatory path, we need such a platform and a whole parallel infrastructure?

Liz Parrish: I realized that quite early in my journey, but it took us a while to organize the right team, and our collaborations.

Ariel Feinerman: How optimistic are you that other companies will follow your way?

Liz Parrish: Very. We think that the anti-ageing and regenerative market with growing at a compound annual growth rate (CAGR) of over 8.4% over the next 5 years, and the total market valuation will reach approximately $500 billion by 2022. We have no doubt that this will encourage many companies all over the world to find innovative ways to capture market share by providing unprecedented value to customers. We hope those companies will use our platform and we can use our years of experience to assist them.

Ariel Feinerman: We already have many amazing results in the lab which can save human lives just now, but lack of funding and the over-regulated medical system don’t give them any chance to be in clinics in coming years. With the current pace of progress, they will already be outdated even before clinical trials. Do you think that translational research becomes the bottleneck?

Liz Parrish: Yes and no. Part of the the bench-to-bedside translational process needs to be expedited, whilst other parts need better oversight, and due-diligence, and yet other parts of the process need to be built from the ground up. BioViva is collaborating with biotech companies, researchers, clinicians, and regulators to put together all these pieces of the translational puzzle in the right place at the right time for the right set of patients to benefit.

Ariel Feinerman: What therapies do you offer now?

Liz Parrish: BioViva doesn’t offer any therapies. We partner with clinics, and other companies, including Integrated Health Systems (IHS), that offer patients treatments in various places in the world. Please contact IHS to receive their treatment details for patients.

Ariel Feinerman: As far as I remember, BioViva worked on telomerase earlier. Does your company work on any therapy now?

Liz Parrish: Our company partnered with Integrated Health Systems (IHS) earlier this year. Our partner company offers treatments in various parts of the world, while BioViva collects and analyses patient data.

Ariel Feinerman: What are your requirements for a bioengineering company that wishes to use your program? How do you ensure that their therapy is safe and effective?

Liz Parrish: We are not a body-hacking or bioengineering company. We collect data from treatments offered at clinics selected by our partner company mentioned above. IHS demands that the clinics conform to their countries’ regulations and medical personnel involved have adequate training, as well as high standards of hygiene and equipment. IHS only works with clinics that have an excellent reputation. US-trained doctors also regularly inspect clinics working for IHS to ensure that standards are maintained.

Ariel Feinerman: I mean can you say how your platform works?

Liz Parrish: Our company business is done by contract. Unfortunately I cannot elaborate on this point because it is not public information. Our goal, when setting up our platform, is to speed up regulation by getting as much early human data as possible that will hopefully make cutting-edge technologies available to those who need them as soon as possible. Ageing kills 100,000 people a day, so we cannot humanely afford to drag our feet; we must get treatments out as soon as they are available.

Ariel Feinerman: Investors usually fear uncertainty which follows companies who choose any alternative to the mainstream regulatory way. Is this improving? How do you solve this problem? Do you help bioengineering companies to look for loyal investors?

Liz Parrish: Any investment in new methods is risky. No risk, no gain. Medicine cannot progress if no one is prepared to take a risk. This applies as much to investors as to patients. Recently however we notice a trend in favour of investments that would have been considered high-risk five years ago but that today are regarded rather as medium-risk. The reason is the increase in computer capacity which in turn allows for more data and therefore for more data analysis. When it comes to data, more is synonymous with better. Lots of data allow investors to better predict the returns on their investments, so more money is invested in endeavours involving lots of data.

Ariel Feinerman: Dr. Aubrey de Grey has said: “I think the key thing we should be doing more of is making better use of those who choose to go abroad to get treated: we should make it as easy as possible for them to report on what treatment they received and how well it worked, any side-effects, etc., for a long time after the treatment, so that such information can be analysed and used to guide future research. The people who provide experimental therapies don’t have any incentive to gather such data themselves, so it usually never gets gathered.”

Do you or your partner clinics gather such information or follow your patients?

Liz Parrish: As I said above, BioViva’s task is the collection and treatment of data. This is what we do. We collect data before and at the time of the treatment, and then at various times after the therapy. We hope to gather much data from each patient we treat, and to gather much data from many, many patients. This is the only way to assess if a treatment works, whom it works for, after how long, how many times, etc.

Ariel Feinerman: Some people express concern that many therapies via medical tourism will be available only for small groups of people, because of lack of information, need to go abroad, lack of established clinic networks, and so on. What can you argue? How can you plan to make them more available?

Liz Parrish: All novel therapies are expensive because the R&D enabling them is still ongoing. The small group of people who can afford them are benefiting from what at the time of their treatment is cutting-edge medicine, but they are simultaneously funding the R&D that will assess these therapies, and later make them affordable to a larger number of people. This is just as true of organ transplants or surgical bypass, now routine but once unaffordable to most, as it is of gene therapy.

The fact that a treatment takes place abroad does not necessarily imply lack of information. All clinics proposed by IHS have websites with detailed information about their facilities. IHS is the clinical network, that hitherto has been lacking, which will connect patients needing treatment to clinics all over the world, one or two of which may have just the treatment a certain patient requires.

For sure, there is less information about the clinical results of some of the treatments they propose, and how could it be otherwise? Those treatments are pioneering, and therefore off the beaten track in novel territory. This novel territory requires patients to explore it, provide data for BioViva to analyse and in this way make the new treatments available to more people.

Ariel Feinerman: Thank you very much for your answers, hope to see you again!

Liz Parrish: Thanks you, it was my pleasure.

Ariel VA Feinerman is a researcher, author, and photographer, who believes that people should not die from diseases and ageing, and whose main goal is to improve human health and achieve immortality.

Message from Ariel VA Feinerman: If you like my work, any help will be appreciated!

PayPal: arielfeinerman@gmail.com

Bitcoin: 1Gz5ebAyPmM9vNAAgpmeX7G3rtKMyWEjb1

Ether: 0x4752d8a8615Cdf48E220f9dbb48654C7791716ee

Bitcoin Cash: qzh427szlnfyk2k6v547gkpjvafnmzgk35hzagzs82

Benefit for U.S. Transhumanist Party Members: Discounts Offered for Treatments from AmpliCell Medical

Benefit for U.S. Transhumanist Party Members: Discounts Offered for Treatments from AmpliCell Medical

AmpliCell Medical


The U.S. Transhumanist Party is pleased to announce that any member who joins us for free via our online application form will also be eligible to receive discounts on procedures from AmpliCell Medical, one of our Allied Organizations, located in the Los Angeles area and specializing in regenerative medicine and stem-cell therapies.

Members who join will receive a confirmation e-mail, which will be sufficient to provide to AmpliCell Medical at the time of a consultation. 

• 40% Discount off of Stem-Cell Treatments: The standard cost is $8,900 for the first treatment and $4,500 for follow-up treatments (if needed). The therapy is investigational and done as part of a clinical trial according to Institutional Review Board (IRB) approved protocols. With the 40% discount, the first treatment would cost $5,340, and a follow-up treatment would cost $2,700.

• 10% Discount off of Bio-Identical Hormone Replacement – First Consultation: The standard cost is $495 for the first consultation. With the 10% discount, that cost would be reduced to $445.50.

Of course, the U.S. Transhumanist Party is not itself a medical organization and does not provide medical advice. Each reader should take account of his or her own individual circumstances, health, medical history, skills, and knowledge when evaluating which courses of action to pursue, and also consult a medical professional with regard to decisions that may have a major impact on health. However, for those individuals whom stem-cell therapies could help, membership in the U.S. Transhumanist Party now offers the opportunity to achieve significant cost reductions in particular treatments.


Description from AmpliCell Medical. Learn more at http://amplicellmedical.com/:

The Fountain of Youth is no longer a myth. It is found within you, in the form of your very own stem cells. Stem cells are our bodies’ own, built-in healing cells, which naturally reside within certain tissues of the body. They start out in a dormant state and are “switched on” by the chemical signals produced by damaged tissues, acting to repair and regenerate damaged cells. Stem cells derived from your own tissues may well be the next major advance in medicine.

While early stem-cell research has been associated with the controversial use of embryonic stem cells, at AmpliCell Medical we use adult mesenchymal cells extracted directly from your own fat. We use a sterile closed surgical system to process 50 cc of fat from a mini-liposuction procedure in order to isolate and implant your own source of regenerative cells on the same day. “Closed surgical system” means that it never comes in contact with the outside world and is kept in a completely sterile environment. The regenerative cells are found in the SVF (stromal vascular fraction) that contains autologous mesenchymal stem cells, macrophage cells, endothelial cells, immune regulatory cells, red blood cells, and important growth factors that promote stem-cell activity. Our technology allows us to isolate high numbers of viable cells.

At AmpliCell Medical we are committed to helping people with wide variety of degenerative and inflammatory conditions. We offer a state-of-the-art minimally invasive procedure that utilizes autologous adipose (fat) derived stem cells.

Diseases and conditions currently being studied:

  • Orthopedics: Neck Arthritis, Back Arthritis, Knee Arthritis, Hip Arthritis, Elbow and Hand Arthritis, Shoulder Arthritis
  • Neurology: Lyme Disease, Peripheral Neuropathy, Multiple Sclerosis, Parkinson’s Disease, Strokes, ALS Amyotrophic Lateral Sclerosis, Muscular Dystrophy
  • Cardiac/Pulmonary: COPD, Post-MI Myocardial Infarction, Congestive Heart Failure and Cardiomyopathy, Chronic Lung Diseases, Asthma
  • Urological and Digestive: Interstitial Cystitis, Peyronies Disease, Erectile Dysfunction, Male Incontinence, Crohn’s Disease
  • Cosmetic Applications: Hair Loss, Skin Health
  • Others: Wellness and Anti-Aging, Hormone Balance, Sport Injuries

THE STUDIED BENEFIT OF STEM-CELL THERAPY

  • Regenerate cells, tissues and organs
  • Repair and reconstruction of joints and strengthening
  • Increase flexibility of joints and articular disc
  • Optimize the immune system
  • Alleviation of menopausal symptoms
  • Improve hormone secretion
  • Increase alertness and mental awareness
  • Refine skin for a healthy glow
  • Improve skin texture, elasticity and thickness
  • Improve sleep pattern
  • Improve blood circulation
  • Enhance stamina and energy
  • Renew sexual abilities and performance
  • Accelerate thinking ability; improve memory

How are stem cells deployed?

There are varying methods for deployment of stem cells based on the condition being treated. The stem cells can be injected directly into joints or even organs as needed, intravenously into the veins, or even into spinal fluid. All redeployment methods are minimally invasive and can be done in outpatient procedures. Since we are using a patient’s own cells, there is no risk of rejection or allergenic reactions that are common in many other procedures.

Will my treatment work, and how long will it take?

Adult stem-cell treatments are currently considered experimental and are not completely understood, how well a patient responds to our treatments will be different in each case and depends greatly on the disease or condition and how severe the case may be. There are regulations by the FDA which will not allow AmpliCell Medical to make any direct claims about the curing or treating any diseases specifically, but, if you want to consult about the procedure, we can lay out expectations based on research data and actual cases prior to treatment.

Stem cells are part of your body’s natural healing process and can take time for effects to take place; however, some conditions can see immediate results.

Who is eligible as a candidate for treatment?

Only specific medical conditions and problems are being treated by AmpliCell Medical at this time. Patients who want to have the treatment done must be medically stable and may be not be able to participate due to the nature and severity of their condition. Any patients that have uncontrolled cancers or active infections are not able to undergo the SVF (Stromal Vascular Fraction) procedure and must have their conditions treated before undergoing the procedure. Another consideration is that patients with bleeding disorders or taking blood-thinner medication must be evaluated before having treatment. When a patient is selected for the procedure, they must keep in mind that they are taking part in patient-sponsored research, and there are no other incentives other than possible results of the treatment.

Read more at AmpliCell Medical’s FAQ here